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IMPORTANCE C-reactive protein (CRP) is a circulating inflammatory marker associated with
late age-relatedmacular degeneration (AMD). It remains uncertain whether the association
between CRP concentrations and AMD is causal.
OBJECTIVE To assess whether CRP (OMIM 123260) single-nucleotide polymorphisms that
influence circulating CRP concentrations are associated with late AMD.
DESIGN, SETTING, AND PARTICIPANTS Participants in 2 UK, hospital-based, case-control
studies (Cambridge AMD study andMoorfields Eye Hospital AMD study) and 1 pan-European,
cross-sectional, population-based study (the European Eye [EUREYE] Study) were recruited
between November 6, 2000, and April 30, 2007. Participants underwent dilated
stereo-digital fundus photography graded according to the International Classification of
Age-relatedMaculopathy andMacular Degeneration. There were 1727 cases of late AMD (1151
neovascular, 384 geographic atrophy, and 192mixed [neovascular AMD and geographic
atrophy]) and 1153 controls. Early AMD cases (n = 574) were included only from the EUREYE
Study. Data analysis was performed from August 1 to November 30, 2016. Four common
single-nucleotide polymorphisms (rs1205, rs1130864, rs1800947, and rs3093077) were
selected based on demonstrated influence on circulating CRP concentrations in the literature.
In one study, genotyping of rs3093077 failed, and rs1800947 was typed in only 1 study.
MAIN OUTCOMES ANDMEASURES A genetic multiplicativemodel was used for the association
of single-nucleotide polymorphisms with late AMD adjusted for age and sex.
RESULTS Among the 1727 patients with late AMD, themean (SD) age was 78.7 (7.4) years, and
668 (38.7%) weremen. Themean (SD) age of the controls was 74.9 (7.0) years, and 510
(44.2%) weremen. In the pooled results of all 3 studies, neither rs1205 (odds ratio [OR],
0.99; 95% CI, 0.86-1.14) nor rs1130864 (OR, 0.96; 95% CI, 0.83-1.11) was associated with late
AMD. For geographic atrophy, rs1205 had an OR of 0.91 (95% CI, 0.74-1.13) and rs1130864
had an OR of 0.94 (95% CI, 0.76-1.16). For neovascular AMD, rs1205 had an OR of 1.01 (95%
CI, 0.87-1.19) and rs1130864 had an OR of 0.99 (95% CI, 0.84-1.16). There was no association
of rs3093077 and rs1800947 with late AMD or any late AMD phenotype. There were no
significant findings for early AMD.
CONCLUSIONS AND RELEVANCE Our results do not support a causal association between CRP
concentrations and AMD.
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I nflammation has been recognized to play a key role in age-relatedmaculardegeneration (AMD),1,2 strengthenedbythediscoveryofmultiplegeneticrisk loci involvedinthecomple-
mentpathway.3-7 Theearly and intermediate stagesofAMDare
characterizedbydrusen,whichareaccumulationsof lipidsand
proteins that form discrete deposits under the retinal pigment
epithelium, and these accumulations can both initiate and
reflect inflammatoryreactionswithinthecomplementpathway.1
Several studies have investigated the association between cir-
culating inflammatory markers and the onset and progression
of AMD,8-12 both to understand the pathogenesis of AMD and
to assess their potential as prognostic biomarkers. One such in-
flammatorymarker is C-reactive protein (CRP), an acute phase
reactant13 that has been shown in 2meta-analyses to be associ-
atedwith lateAMD.14,15C-reactiveprotein is involved in the ini-
tiation and modulation of the classical complement pathway,
as well as the alternative complement pathway, through bind-
ing with complement factor H (CFH [OMIM 134370]). There-
fore, it could be postulated that high concentrations of CRP
play a causal role in the development of AMD by altering
complement-related inflammatory responses to drusen.
DemonstrationofacausalroleofCRPinAMDisproblematic,
asisillustratedbytheabundantworkperformedonCRPandcoro-
naryheartdisease (CHD).Despite thenumerousstudies (includ-
ingmanyprospectivestudies)consistentlyshowinganincreased
riskofCHDwithincreasingCRPconcentrations,16nostudieshave
demonstratedanassociationbetweensingle-nucleotidepolymor-
phisms (SNPs) in theCRP gene and the risk of CHD.17,18 This ap-
proach,describedasMendelian randomization,19 showed that,
althoughcertainCRPSNPshavebeenshowntoinfluencethecon-
centrationsofcirculatingCRP,20thelackofanassociationbetween
thoseCRPSNPsandCHDsuggests thatCRP isunlikely tohavea
causal influenceonCHD.17Akeypoint intheMendelianrandom-
izationapproachisthatthecausalroleofariskexposureforaspe-
cificdiseaseisassessedbytestingtheassociationbetweengenetic
variants(thathavebeenreliablyshowntoinfluencetheexposure)
and the disease of interest. The Mendelian randomization ap-
proachavoids bias due to reverse causationbecause genotypes
arefixedatconceptionand,therefore,arenotsubjecttoconfound-
ing ormodification by the onset of disease.21
Three previous studies have investigated the association
betweenCRP genetic variants andAMD, but nonehave found
an association.22-24 The total number of late AMDcases in the
3 studieswas 394, andeach studymayhave lackedpower.We
investigated the association betweenAMDandCRPpolymor-
phisms in3studies: theEuropeanEye (EUREYE)Study,across-
sectional, population-based epidemiologic study of AMD
prevalence and risk factors,25 and2hospital-basedAMDcase-
control studies, theCambridgeAMDstudy7and theMoorfields
Eye Hospital (MEH) AMD study.26
Methods
For all 3 studies, ethical approval was obtained from either
national or local ethics committees (for the Cambridge AMD
study, Anglia and Oxford Multicentre Research Ethics Com-
mittee; for the MEH AMD study, Moorfields andWhittington
Local Research Ethics Committee; and for the EUREYE study,
the local ethics committees of all 7 participating centers in
7 different countries). The study adhered to the tenets of the
Declaration of Helsinki.27 All participants provided written
informedconsent toundergo theclinical examinationandepi-
demiologic data collection and to provide a blood sample for
biochemical and genetic analyses.
The EUREYE Study
ParticipantswererecruitedbetweenNovember6,2000,andNo-
vember 15, 2002, by random sampling of the population
65 years of age or older in the following 7 centers: Bergen
(Norway), Tallinn (Estonia), Belfast (United Kingdom), Paris-
Creteil (France), Verona (Italy), Thessaloniki (Greece), and
Alicante (Spain). The methods have been published in full
elsewhere.25 Trained field workers administered structured
questionnaires including smoking status, diet, sunlight expo-
sure, andself-reportedmedicalhistory.Theophthalmicexami-
nation included dilated stereo-digital fundus photography.
Stereo fundus images were graded at a single reading center
(Erasmus University Rotterdam) according to the Interna-
tional Classification of Age-related Maculopathy and Macular
Degeneration28 and then categorized into 5 mutually exclu-
sive grades. Grade 0 was defined as a macula free of
drusen or pigmentary irregularities or with hard drusen
(<63μm)only. EarlyAMDwas subdivided intograde 1, defined
as soft distinct drusen (≥63 μm) or pigmentary abnormalities;
grade 2, defined as soft indistinct drusen (≥125 μm), reticular
drusen only, or soft distinct drusen (≥63 μm)with pigmentary
abnormalities; and grade 3, defined as soft indistinct drusen
(≥125 μm) or reticular drusen with pigmentary abnormalities.
Grade4wasdefinedas thepresenceofeitherneovascularAMD
(nvAMD; the presence of any of the following: serous or hem-
orrhagic retinal or retinal pigment epithelial detachment, sub-
retinalneovascularmembrane,orperiretinal fibrousscar)orgeo-
graphic atrophy (GA; well-demarcated area of retinal pigment
atrophywith visible choroidal vessels).
In the present analysis, for reason of costs, a random
sample of controls (AMD stage 0) was frequencymatched on
age (within 1year), sex, andcenterwithpatientswith lateAMD
(nvAMD or GA) and patients with early AMD (stages 2 and 3).
Nonfasting venous blood samples were collected at the oph-
thalmologic examination and separatedwithin4hours of col-
lection. Serum was stored at –20°C for up to 4 weeks before
Key Points
Question Are variants in the C-reactive protein (CRP) gene that are
known to influence circulating C-reactive protein concentrations
associatedwith late age-relatedmacular degeneration?
Findings This pooled analysis examined 4 CRP variants among
1727 patients with late age-relatedmacular degeneration and 1153
controls from 2 hospital-based case-control studies and 1 cross-
sectional population-based study. No statistical associationwas
found between these CRP variants and any type of late age-related
macular degeneration.
Meaning CirculatingC-reactiveproteinconcentrationsareunlikely to
be causally associatedwith age-relatedmacular degeneration.
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frozensampleswere transferred toa single laboratory (Queens
University Belfast) for storage at –80°C.
The Cambridge AMD Study
TheCambridgeAMDstudy is a case-control studyofAMDwith
participants recruited fromophthalmic clinics in London, the
southeast of England, and the northwest of England between
November 1, 2001, andApril 30, 2007.7All patientshadat least
1 eye affected by nvAMDand/or GA. Patientswere excluded if
they had greater than 6 diopters of myopic refractive error or
evidenceofother inflammatoryor retinovasculardisease (such
as retinal vessel occlusion, diabetic retinopathy, or chorioreti-
nitis) that could contribute to the development of or con-
found the diagnosis of maculopathy. Almost all of the con-
trols were spouses or partners of index patients, and the
remainder were friends of patients. All participants de-
scribed their race/ethnicity aswhite rather than other on a re-
cruitment questionnaire. Participants were examined by an
ophthalmologist and underwent color stereoscopic fundus
photography of the macular region. Health, lifestyle, and
smoking data were also collected from the participants.
Imagesweregradedat theReadingCentre,MEH,London,using
the InternationalClassificationofAge-relatedMaculopathyand
Macular Degeneration.28 Blood samples were obtained at the
time of interview; EDTA samples were obtained for DNA
extraction, and lithium-heparin plasma samples stored at
–80°C were later used for CRPmeasurements.
TheMEHAMD Study
The MEH AMD study is a case-control study of AMD under-
taken at MEH, London, between February 1, 2001, and Janu-
ary 31, 2004.26 Only patients and controls of European origin
were included inthestudy.Patientsattendingroutine follow-up
appointments and all new referrals from primary care clinics,
casualty, and other centers with any type of AMD were en-
rolledtotryto limitselectionbias.Patientswereexcludedif they
had retinochoroidal inflammatory disease, diabetic retinopa-
thy, branch retinal vein or artery occlusion, or any other cause
ofvisual lossotherthanamblyopia.Controlswererecruitedfrom
spouses or friends of patients or from local residential homes
for elderly persons within 8 km (5miles) of the hospital. Each
participantwas interviewedspecifically for thestudy,andafam-
ilyhistory, smokinghistory, andothermedicalhistorywereob-
tained. The ophthalmic examination included Snellen acuity,
slitlampexamination,andbiomicroscopicophthalmoscopy.All
participants underwent color stereoscopic fundus photogra-
phy of the macular region, and the images were graded at
the Reading Centre, MEH, London, using the International
Classification of Age-related Maculopathy and Macular
Degeneration.28 Controls were excluded if drusen larger than
63 μm were evident. A sample of peripheral blood was
obtained from each participant and stored at –20°C for DNA
extraction and –80°C for analytemeasurement.
Circulating CRP Concentrations
CirculatingCRPconcentrationsweremeasured in theEUREYE
and Cambridge AMD studies. In the EUREYE Study, the con-
centrations of serum CRP were assessed by a high-sensitivity,
latex-enhanced turbidometric immunoassay (Wako Chemi-
cals GmbH) using a Cobas Fara analyzer (Roche Diagnostics).
In the Cambridge AMD study, the concentrations of plasma
CRP were measured by a high-sensitivity, particle-enhanced
immunonephelometric assay (Siemens CardioPhase hsCRP;
SiemensMedical Solutions)usingaSiemensDadeBehringBNII
Nephelometer.ParticipantswithCRPlevelshigher than10mg/L
(to convert CRP to nanomoles per liter, multiply by 9.524), in-
dicative of acute infection,29were not included in the analysis
(90 from the EUREYE Study and 51 from the Cambridge AMD
study).C-reactiveproteinconcentrationswerenatural logarith-
mically transformedtoensurenormalityof thedistributionand
further Z transformed for investigation of the association of a
1-SD increase in log CRPwith AMD.
Genotyping
Wechose4 commonSNPs (rs1205, rs1130864, and rs1800947
in the3′UTR[untranslatedregion]andsynonymousrs3093077
in exon 2) in the CRP gene previously reported in a meta-
analysis on CRP and CHD using a Mendelian randomization
approach.17 These variants were selected as the most parsi-
monious set of tagging SNPs capturing maximum haplotype
diversity and of demonstrated association with CRP concen-
trations among individuals of European descent.21,30 The
EUREYE Study samples were genotyped at LGC Genomics
(Hoddesdon, England) using KASPar chemistry, a competi-
tive allele-specific polymerase chain reaction SNP genotyp-
ing system using fluorescence resonance energy transfer
quencher cassette oligos. Genotyping in the Cambridge AMD
study was carried out using the ABI PRISM SNaPshot ddNTP
Primer Extension Kit and a 3100 Genetic Analyzer (Applied
Biosystems). Genotyping in the MEH AMD study was carried
out using a Taqman (ABI) assay (Applied Biosystems). Depar-
ture from Hardy-Weinberg equilibrium was assessed for all
SNPs in the control groups using a χ2 goodness-of-fit test.
Statistical Analysis
Statistical analysis was performed from August 1 to Novem-
ber 30, 2016. We investigated the association of CRP geno-
typewith lateAMDandby lateAMDphenotype (GAornvAMD).
We also report results for early AMD (available in the EUREYE
Studyonly).All associationanalyseswereconductedas2-stage,
fixed-effectsmeta-analysis of the available individual partici-
pant data from the 3 studies. Heterogeneity across study cen-
ters was assessed using the I2 statistic. We calculated odds
ratios (ORs) and their corresponding95%CIs using logistic re-
gressionmodels adjusted for sex andage.Odds ratioswere ex-
pressed as per 1 minor allele (multiplicative genetic model).
To confirm that, in our studypopulation, the selectedSNP
genotypes influence circulating CRP concentrations, we ex-
amined the association ofCRP genotypewith CRP concentra-
tions in controls via aWald test on the genotype coded as 0, 1,
and 2 according to the number of minor alleles using linear
regression models adjusted for age and sex. We report geo-
metric mean (SD) values for concentrations by genotype.
For comparison with previous studies, we analyzed the
associationofCRPconcentrationswith lateAMDand lateAMD
phenotype using logistic regression models. These analyses
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wereadjusted forageandsexand,additionally, for apriori con-
founders includinghistory ofmyocardial infarctionor stroke,
diabetes, and smoking.Odds ratioswere expressedasper 1-SD
change of log CRP concentration.
All statistical analyses were conducted using Stata soft-
ware,version13.1 (StataCorp), and ipdmetanandmvmetacom-
mandswere used for conductingmeta-analyses of individual
participant data. P < .05 was considered significant.
Results
Therewere 1727 cases of lateAMD (1151 neovascular, 384 geo-
graphic atrophy, and 192 mixed [neovascular AMD and geo-
graphic atrophy]) and 1153 controls. Among the 1727 patients
with lateAMD, themean (SD) agewas 78.7 (7.4) years, and668
(38.7%)weremen. Themean (SD) age of the controlswas 74.9
(7.0) years, and 510 (44.2%) weremen. The characteristics of
the participants and the genotype frequencies by study are
shown in Table 1. Genotyping of rs3093077 failed in the
EUREYEStudy, and rs1800947wasnot typed in theMEHAMD
study and theCambridgeAMDstudy. In each study, nodevia-
tion from Hardy-Weinberg equilibrium was observed for any
SNP,andcontrolminimumallele frequencies (MAF)weresimi-
lar both between studies and to those reported for the 1000
GenomesProject31,32 Phase 3European (EUR) samples: rs1205
MAF(Tallele),0.34; rs1130864MAF(Tallele),0.33; rs3093077
MAF(Gallele),0.07; andrs1800947MAF(Callele),0.05.There
were significant associations in the pooled analysis for the
rs1205 T allelewith lower CRP concentrations in controls and
for the rs1130864 T allele with higher CRP concentrations in
controls (Table 2). For the 2 rarer SNPs rs3093077 and
rs1800947, there was no association with CRP concentra-
tions in controls.
There was no evidence of any association of CRP SNPs
rs1205, rs1130864, or rs3093077 with late AMD, or with type
Table 1. Study Characteristics
Characteristic
EUREYE Study Cambridge AMD Study MEH AMD Study
Controls
(n = 643)
Early AMD
(n = 574)
Late AMD
(n = 152)
Controls
(n = 262)
Late AMD
(n = 427)
Controls
(n = 248)
Late AMD
(n = 1148)
Age, mean (SD), y 74.7 (6.1) 74.6 (5.9) 79.5 (7.2) 75.7 (7.8) 80.4 (6.9) 74.8 (8.0) 77.9 (7.4)
Male, No. (%) 301 (46.8) 279 (48.6) 52 (34.2) 105 (40.1) 196 (45.9) 104 (41.9) 420 (36.6)
CRP, geometric
mean (SD), mg/L
1.88 (1.21) 1.90 (1.28) 1.99 (1.35) 1.84 (1.72) 2.15 (1.92) NA NA
rs1205, No./Total No. (%)
CC 273/612 (44.6) 246/560 (43.9) 58/146 (39.7) 119/256 (46.5) 200/419 (47.7) 101/231 (43.7) 478/1084 (44.1)
CT 267/612 (43.6) 240/560 (42.9) 75/146 (51.4) 113/256 (44.1) 183/419 (43.7) 107/231 (46.3) 507/1084 (46.8)
TT 72/612 (11.8) 74/560 (13.2) 13/146 (8.9) 24/256 (9.4) 36/419 (8.6) 23/231 (10.0) 99/1084 (9.1)
P value for HWE in controls .36 NA NA .70 NA .49 NA
MAF in controls 0.35 NA NA 0.31 NA 0.33 NA
rs1130864,
No./Total No. (%)
CC 280/610 (45.9) 265/557 (47.6) 68/147 (46.3) 126/262 (48.1) 188/423 (44.4) 104/233 (44.6) 528/1084 (48.7)
CT 266/610 (43.6) 245/557 (44.0) 68/147 (46.3) 113/262 (43.1) 204/423 (48.2) 108/233 (46.4) 451/1084 (41.6)
TT 64/610 (10.5) 47/557 (8.4) 11/147 (7.4) 23/262 (8.8) 31/423 (7.3) 21/233 (9.0) 105/1084 (9.7)
P value for HWE in controls .73 NA NA .74 NA .35 NA
MAF in controls 0.35 NA NA 0.30 NA 0.32 NA
rs3093077,
No./Total No. (%)
TT NAa NAa NAa 232/262 (88.5) 380/425 (89.4) 211/233 (90.6) 960/1085 (88.5)
GT NAa NAa NAa 30/262 (11.5) 45/425 (10.6) 21/233 (9.0) 119/1085 (11.0)
GG NAa NAa NAa 0 0 1/233 (0.4) 6/1085 (0.5)
P value for HWE in controls NA NA NA .33 NA .55 NA
MAF in controls NA NA NA 0.06 NA 0.05 NA
rs1800947,
No./Total No. (%)
GG 519/585 (88.7) 471/539 (87.4) 113/136 (83.1) NA NA NA NA
CG 63/585 (10.8) 65/539 (12.1) 21/136 (15.4) NA NA NA NA
CC 3/585 (0.5) 3/539 (0.6) 2/136 (1.5) NA NA NA NA
P value for HWE in controls .50 NA NA NA NA NA NA
MAF in controls 0.07 NA NA NA NA NA NA
Abbreviations: AMD, age-relatedmacular degeneration; CRP, C-reactive protein; EUREYE, European Eye; HWE, Hardy-Weinberg equilibrium; MAF, minor allele
frequency; MEH, Moorfields Eye Hospital; NA, not available.
SI conversion factor: To convert C-reactive protein to nanomoles per liter, multiply by 9.524.
a Genotyping for rs3093077 failed.
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of lateAMD, either from the individual studies or in themeta-
analysis, or for SNP rs1800947 in theEUREYEStudy (Table 3).
A significant associationwas observed in the pooled age-
andsex-adjustedanalysisofCRPconcentrationswith lateAMD
(Table 4). Additional adjustment for smoking, myocardial
infarction and stroke, and diabetes slightly reduced the ORs
(from 1.19 to 1.16), and the P value changed from0.03 to 0.07.
Analyses of CRP concentrations by type of late AMD showed
that GA had an OR of 1.35 (95%CI, 1.03-1.76; P = .03) and that
nvAMD had an OR of 1.09 (95% CI, 0.91-1.29; P = .36).
Only theEUREYEStudyhadpopulation-baseddata avail-
able on early AMD. There was no association of CRP concen-
trations with early AMD in age- and sex-adjusted or fully ad-
justed analyses (OR, 1.01; 95%CI, 0.82-1.25;P = .90) or of any
CRP SNPs with early AMD (rs1205: OR, 1.08; 95% CI, 0.98-
1.20; P = .13; rs1130864: OR, 0.89; 95% CI, 0.75-1.06; P = .20;
and rs1800947: OR, 1.20; 95% CI, 0.89-1.63; P = .23).
Discussion
In this meta-analysis of 3 studies of AMD including 1727 pa-
tientswith late AMDand 1153 controls, we foundno evidence
from analysis of CRP variants to support a causal association
of CRP concentrationswith late AMD, either nvAMDorGA. In
agreement with many other studies,17,18,33 we found that the
T allele of rs1205 was associated with lower CRP concentra-
tions in controls. However, there was no protective associa-
tionbetween theTallele andeithernvAMDorGA in anyof the
3 studies. Similarly, the T allele of rs1130864 was associated
withhigherCRPconcentrations incontrols, but theTallelewas
notassociatedwithhigheroddsofeither lateAMDphenotype.17
None of the 3 previous studies that investigatedCRP poly-
morphisms and AMD found an association.22-24 These studies
had smaller sample sizes than our investigation and included
two23 or three22,24 of the SNPs we investigated (rs1205,
rs1130864, and rs1800947). In a case-control study (111mixed
early and late cases and 401 controls) nested within the pro-
spective follow-upof thePhysiciansHealthStudy,AMDriskwas
not influenced by any of 7CRP SNPs24 or by any of 9CRP SNPs
inasib-pair studyof112casesofnvAMD.22TheRotterdamstudy
(5861participants, including 171with lateAMD) suggested that
CRP haplotypes may modify the association of CFH Y402H
genotypewith lateAMD, but theCRPhaplotypesdidnot influ-
enceAMDriskdirectly; resultswerenotpresented for the3CRP
SNPs individually.23 Inaddition, ameta-analysis of 15genome-
wide association studies (GWASs)34 and a recent large GWAS
(16 144patients and17832controls)35 ofAMDdidnot showany
genome-wide significant association signals at the CRP locus.
In our fully adjusted association analyses between CRP
concentrations and AMD, we did not find a significant asso-
ciation with all cases of late AMD (P = .07; 1324 patients, in-
cluding 489 with late AMD) and nvAMD (P = .36; 318 pa-
tients)orwithearlyAMD(P = .90;574patients),whichhasbeen
reported in other studies.9,15,36 The association with AMD is
not consistent, particularly in studies investigating early
AMD.11,37-40 In a largemeta-analysis comparing low (<1mg/L)
vs high (>3 mg/L) CRP concentrations, Hong et al14 reported
anORof1.30(95%CI, 1.03-1.65) in3studies thatcombinedearly
and late AMD (4522 patients, including 1629 with AMD) and
anORof2.19 (95%CI, 1.38-3.47) in8studiesof lateAMD(35 168
patients, including 1603 with AMD). Estimates for late AMD
varied considerably according to method of AMD ascertain-
ment,withmuchhigherORsreportedforclinicaldiagnosis (3.8)
comparedwith fundusphotography (1.4), adjustment for dia-
betes (1.6) comparedwith no adjustment (2.5), and study de-
sign. Population-based cross-sectional or case-control stud-
ies had lower ORs than did clinic case-control studies or
longitudinal studies. Inapooledanalysisofprospective,nested
case-control studies from5population-basedUS cohorts (647
patients, including 190 with nvAMD), CRP concentrations
above 3 mg/L were associated with risk of all late AMD and
nvAMD compared with concentrations less than 1 mg/L.15
Table 2. CRP Concentrations by Genotypes of CRP SNPs in Controls
CRP SNPs
EUREYE Study Cambridge AMD Study
No.
CRP, Geometric
Mean (SD),
mg/L No.
CRP, Geometric
Mean (SD),
mg/L
rs1205
CC 255 2.05 (1.36) 105 1.97 (1.83)
TC 249 1.79 (1.10) 96 1.82 (1.77)
TT 67 1.65 (1.01) 21 1.28 (1.25)
P value for trend of CRP
concentration across
genotypesa
NA .003 NA .13
Pooled P value for trend
of CRP concentration
across genotypesb
.001
rs1130864
CC 264 1.87 (1.24) 110 1.43 (1.42)
TC 248 1.84 (1.09) 94 2.32 (2.11)
TT 56 2.26 (1.65) 21 2.19 (1.29)
P value for trend of CRP
concentration across
genotypesa
NA .19 NA .002
Pooled P value for trend
of CRP concentration
across genotypesb
.01
rs3093077c
TT NA NA 200 1.82 (1.72)
GT NA NA 25 1.83 (1.91)
GG NA NA 0 NA
P value for trend of CRP
concentration across
genotypesa
NA NA NA .83
rs1800947
GG 486 1.87 (1.20) NA NA
GC 56 2.15 (1.30) NA NA
CC 3 1.11 (0.74) NA NA
P value for trend of CRP
concentration across
genotypesa
NA .46 NA NA
Abbreviations: AMD, age-relatedmacular degeneration; CRP, C-reactive
protein; EUREYE, European Eye; NA, not available; SNPs, single-nucleotide
polymorphisms.
SI conversion factor: To convert C-reactive protein to nanomoles per liter,
multiply by 9.524.
a From age- and sex-adjusted regressionmodel of log CRP concentration in each
study.
b From age- and sex-adjusted regressionmodel of log CRP concentration in
meta-analysis.
c Genotyping for rs3093077 failed.
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Limitations
Althoughour studywas larger than the3previous studies that
investigated the association between CRP variants and AMD,
it does have several limitations, especiallywith respect to the
association between CRP concentrations and AMD. In the
EUREYE and Cambridge studies, the blood samples used for
measuringCRPconcentrationswerecollectedat the sametime
as ascertainmentofAMD, and thereforewecannot exclude re-
verse causation (eg, an inflammatory response)due to risk fac-
tors for AMD, such as atherosclerosis and cardiovascular dis-
ease.Weonly had 1measure of CRP,whichmaynot represent
longer-termusual concentrations. In addition, circulatingCRP
concentrations may not adequately reflect the CRP concen-
tration in the relevant tissues.Themonomeric formofCRPhas
been shown to be responsible for the upregulation of pro-
inflammatory cytokines interleukin 8 and chemokine ligand
2 in retinal pigment epithelial cells, and patients with AMD
carrying the risk variants of CFH Y204H showed impaired
binding of monomeric CRP.41
Genetic variants in CRP are not subject to reverse
causation19,21 and, therefore, provide stronger evidence on
the possible association of CRP concentrations with AMD.
We investigated only a small number of CRP SNPs. Never-
theless, we selected SNPs expected to show a causal asso-
ciation with AMD because these SNPs influence CRP
concentrations.17,20,21,30 Variants associated with CRP con-
centrations in other loci have been identified in large
GWASs and replication studies.18,42 These variants are
found in genes primarily involved in lipid, metabolic, or
immune pathways and include IL6R (OMIM 147880),
HNF1A (OMIM 142410), and APOCI (OMIM 107710). In a
GWAS of CHD, the APOC1 variant (rs4420638) was associ-
ated with increased risk of CHD but in an opposite direction
to that anticipated from its association with CRP and consis-
tent with its association with low-density lipoprotein and
high-density lipoprotein cholesterol and triglycerides.18
This variant has also been identified at genome-wide signifi-
cance to increase the risk of AMD.34 APOC1 is part of the
apolipoprotein gene cluster that plays a major role in lipid
transport and metabolism and includes the well-established
APOE (OMIM 107741) AMD risk variant (rs429358).43 Link-
age disequilibrium (r2 = 0.7)44 is observed between
rs4420638 and rs429358 in the EUR populations from
Phase 3 of the 1000 Genomes Project.31,32
Table 3. Association of CRP SNPsWith Late AMD in the EUREYE Study, Cambridge AMD Study, andMEHAMD Study
SNP
EUREYE Studya Cambridge Studya MEH Studya Pooleda
OR (95% CI) P Value OR (95% CI) P Value OR (95% CI) P Value OR (95% CI) P Value
Late AMD
rs1205 1.06 (0.80-1.40) .69 0.95 (0.73-1.22) .66 0.98 (0.78-1.23) .87 0.99 (0.86-1.14) .88
rs1130864 0.86 (0.64-1.16) .33 1.17 (0.90-1.52) .24 0.89 (0.71-1.11) .29 0.96 (0.83-1.11) .60
rs3093077 NA NA 0.92 (0.55-1.54) .76 1.26 (0.80-1.98) .32 1.10 (0.78-1.55) .59
rs1800947 1.54 (0.95-2.50) .08 NA NA NA NA NA NA
Neovascular AMD
rs1205 1.04 (0.75-1.44) .81 0.99 (0.76-1.30) .96 1.02 (0.80-1.29) .88 1.01 (0.87-1.19) .85
rs1130864 0.83 (0.58-1.17) .28 1.29 (0.97-1.71) .08 0.90 (0.71-1.13) .35 0.99 (0.84-1.16) .86
rs3093077 NA NA 1.02 (0.59-1.77) .95 1.25 (0.78-2.01) .35 1.15 (0.80-1.64) .45
rs1800947 1.68 (0.97-2.93) .06 NA NA NA NA NA NA
Geographic atrophy
rs1205 1.11 (0.71-1.74) .65 0.91 (0.60-1.38) .65 0.85 (0.64-1.13) .26 0.91 (0.74-1.13) .40
rs1130864 0.98 (0.61-1.60) .95 1.18 (0.79-1.76) .42 0.83 (0.62-1.10) .20 0.94 (0.76-1.16) .59
rs3093077 NA NA 0.73 (0.29-1.84) .51 1.62 (0.94-2.77) .08 1.31 (0.83-2.10) .25
rs1800947 1.37 (0.62-3.04) .43 NA NA NA NA NA NA
Abbreviations: AMD, age-relatedmacular degeneration; EUREYE, European Eye; MEH, Moorfields Eye Hospital; NA, not available; OR, odds ratio;
SNP, single-nucleotide polymorphism.
a Sex- and age-adjusted OR and P value for a genetic multiplicative model.
Table 4. Association of C-Reactive Protein ConcentrationWith Late AMD
Value
Late AMD Neovascular AMD Geographic Atrophy
EUREYE
Study
Cambridge
AMD Study
Pooled
(n = 1324)
EUREYE
Study
Cambridge
AMD Study
Pooled
(n = 1153)
EUREYE
Study
Cambridge
AMD Study
Pooled
(n = 946)
OR (95% CI)a,b 1.17
(0.89-1.56)
1.20
(1.00-1.45)
1.19
(1.02-1.39)
1.09
(0.79-1.51)
1.13
(0.93-1.38)
1.12
(0.95-1.33)
1.33
(0.84-2.09)
1.48
(1.09-2.02)
1.43
(1.11-1.84)
P value .26 .05 .03 .59 .23 .19 .22 .01 .006
OR (95% CI)c 1.10
(0.82-1.47)
1.18
(0.98-1.43)
1.16
(0.99-1.36)
1.00
(0.71-1.41)
1.12
(0.91-1.37)
1.09
(0.91-1.29)
1.26
(0.79-2.03)
1.39
(1.01-1.92)
1.35
(1.03-1.76)
P value .54 .08 .07 .99 .29 .36 .33 .05 .03
Abbreviations: AMD, age-relatedmacular degeneration; EUREYE, European
Eye; OR, odds ratio.
a Odds ratio per 1-SD change in log C-reactive protein concentration.
bAdjusted for age and sex.
c Adjusted for age, sex, diabetes, cardiovascular disease, and smoking status.
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Conclusions
From the analogy with CHD17 and the identification of alter-
native genetic loci for CRP concentrations already dis-
cussed, along with the lack of association of variants in the
CRP locus with AMD shown in our meta-analysis corrobo-
rating results from previous studies, we conclude that
CRP concentrations are unlikely to be causally associated
with AMD.
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Invited Commentary
Association Between C-Reactive Protein and Age-Related
Macular Degeneration
Les Liaisons Dangereuses
Tiarnán D. Keenan, MD, PhD; Emily Y. Chew, MD
Triangular relationshipsmightmake life interesting, but they
canbehard tountangle. In this issueof JAMAOphthalmology,
Cipriani et al1 have conducted an elegant study examining
the triangular association
between circulating concen-
trations of C-reactive protein
(CRP), CRP (OMIM 123260)
genetic variants, and risk of late age-related macular degen-
eration (AMD) (choroidal neovascularization or central geo-
graphic atrophy). Their findings have important implications
for our understanding of the pathophysiology of AMD,
particularly the distinction between systemic and local
inflammation.
The authors pooled data from 3 European studies to test
potential associations in this triangular affair. Two CRP ge-
netic variants did share someassociationwith circulatingCRP
concentrations (in control participants). However, no genetic
variantwas significantly associatedwith the risk ofAMD;pre-
viousobservers2havealsosearched for this association invain.
In any case, as the authors helpfully pointed out by analogy
with cardiovascular research, there is a big difference
between association and causation.
InthestudybyCiprianietal,1 circulatingCRPconcentrations
were weakly associated with geographic atrophy, along partly
similar lines to thoseof findings for lateAMD in someprevious
studies. It is important to remember, however, that circulating
Related article page 909
Research Original Investigation Association of C-Reactive Protein Genetic PolymorphismsWith Late Age-RelatedMacular Degeneration
916 JAMAOphthalmology September 2017 Volume 135, Number 9 (Reprinted) jamaophthalmology.com
© 2017 American Medical Association. All rights reserved.
Downloaded From:  by a University College London User  on 10/19/2017
